Gold Standard Diagnostics, a Eurofins Technologies Company, Launches CE Marked Assay for the Detection of the Omicron SARS-CoV-2 Variant
14.12.2021 11:00:00 EET | Business Wire | Press release
Gold Standard Diagnostics continues its response to the threat of the emerging Omicron SARS-CoV-2 variant by providing innovative diagnostic solutions.
The Omicron SARS-CoV-2 variant has raised significant concerns given its rapid spread in South Africa and has now been confirmed in over 40 countries. The variant contains many mutations which may enable the virus to evade the immune response raised by previous infection or vaccination.
With the current uncertainty surrounding the dangers of the Omicron SARS-CoV-2 variant, it is crucial to closely monitor its spread and provide reliable diagnostic solutions for its identification. By now, the variant has already split in two sublineages (BA.1 & BA.2) one of which, nicknamed the ‘stealth Omicron’, does not carry the Spike protein deletion 69/70. This deletion, however, has so far been used as a workaround to identify this variant through a dropout in a widely used RT-PCR assay [1].
Gold Standard Diagnostics Europe now offers a rapid and reliable RT-PCR assay detecting Omicron SARS-CoV-2 variant, including both sublineages. GSD NovaType II SARS-CoV-2 specifically identifies mutations N501Y and K417N, present in Omicron in approximately 1 hour, much faster than genome sequencing methods. The assay is CE-marked and available immediately.
GSD NovaType II SARS-CoV-2 supplements the product range developed in response to emerging SARS-CoV-2 variants, such as GSD NovaType Detect & Select K417N SARS-CoV-2 (RUO), that combines SARS-CoV-2 detection and identification of an Omicron signature mutation in one reaction.
Reference
[1] https://github.com/cov-lineages/pango-designation/issues/361
For more information, please visit Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005150/en/
Contact information
For further information:
Rodrigo Berlie
ir@eurofins.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 17:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application and scale, we are well-positioned to help our customers translate th
Andersen Consulting Strengthens Capabilities with Addition of Lukkap31.3.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm Lukkap, a consultancy focused on experience-driven capabilities aligned with clients’ evolving people, customer, and digital transformation needs. Founded in 2009 and headquartered in Spain, Lukkap delivers integrated solutions that help organizations transform how they serve customers, engage employees, and unlock value through behavioral insights and data analytics. The firm’s multidisciplinary approach spans customer journey redesign, high-impact employee experience programs, talent and leadership development, predictive analytics, and comprehensive outplacement and transition services. Lukkap works across sectors — including healthcare, pharmaceutical, consumer goods, retail, finance, and banking — to build human-centered strategies that drive measurable business results. “By combining our experience-led methodology with Andersen Consulting’s global platform, we can accelerate the way organizations approach customer experience,” said Albe
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 16:26:00 EEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 16:25:00 EEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 16:00:00 EEST | Press release
Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartner. “By redefining partner marketing automation and embedding it directly into our revenue orchestration platform, we en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom